Post on 29-Dec-2015
transcript
PHARMACOVIGILANCE AND CLINICAL TRIALS
DIVISION20 August 2015
Victoria Falls
Protecting Your Right to Quality Medicines and Medical Devices
Activities Of The PVCT Division
• Pharmacovigilance Activities
• Regulation Of Clinical Trials Involving Medicines And Medical Devices
PHARMACOVIGILANCE
Pharmacovigilance: is the science and activities relating to the detection
collectionassessmentmonitoring, andprevention
of adverse effects related to pharmaceutical products and communication in a way that improves therapeutic outcomes (W.H.O)
Protecting Your Right to Quality Medicines and Medical Devices
Adverse Drug Reactions (ADRs)
• Any response to a drug which is noxious and unintended, including lack of efficacy, which occurs at doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological function
Protecting Your Right to Quality Medicines and Medical Devices
Spontaneous report
(ICSR - individual case safety report)
‘an unsolicited communication by healthcare professionals or consumers that describes one or more adverse drug reactions in a patient who was given one or more medicinal products and that does not derive from a study or any organised data collection scheme’
Targeted spontaneous report
‘a spontaneous report from a healthcare professional or consumer within a defined cohort that describes one or more adverse drug reactions in a patient who was given one or more medicinal products’
Importance of reporting
• generation of “signals”• influence drug labelling • Documentation of previously unknown ADRs• Withdrawal of drugs e.g dextropropoxyphene (Doxypol)• Ultimately, improved therapeutic outcomes
Protecting Your Right to Quality Medicines and Medical Devices
What is a signal?
CHALLENGE QUESTION (Adapted from the FDA)
A safety “signal” is defined as:A. New, previously unknown, adverse eventB. New drug interactionC. An observed increase, either in quantity or severity, of a known
adverse eventD. All of the above
Protecting Your Right to Quality Medicines and Medical Devices
Importance of reporting
There are differences in ADRs among people from different countries or regionsUsually due to differences in • diseases and prescribing practices;• genetics, • diet, • traditions of the people;• drug manufacturing processes
Protecting Your Right to Quality Medicines and Medical Devices
Importance of reporting
• Data derived from within the country or region may have greater relevance and educational value and may encourage national regulatory decision-making.
• Information obtained in one country (e.g. the country of origin of the drug) may not be relevant to other parts of the world, where circumstances may differ.
Protecting Your Right to Quality Medicines and Medical Devices
Barriers to ADR Reporting
• We already know the ADR• What benefit is it?• Scared to report• Failure to recognise ADR• All approved medicines are safe notion
Barriers to ADR Reporting
• Not aware of regulations• attitude• Odd reactions• ADRs may mimic a common natural disease• Long delay in the appearance of the Adverse effect• Disease complexity clouds drug-related issues
TSR of anti-TBs and ARVs- Pilot PhaseBackground:
•Adverse drug reaction monitoring is essential in achieving the goals of
anti-retroviral (ARV) and anti-tuberculosis (anti-TB) treatment, and is
an important element in promoting rational medicine use principles and
promoting patient safety.
Protecting Your Right to Quality Medicines and Medical Devices
TSR of anti-TBs and ARVs- Pilot PhaseObjectives:
The pilot phase of the Targeted Spontaneous Reporting (TSR) system
for monitoring adverse drug reactions pilot phase research was carried
out to strengthen pharmacovigilance activities in the National ART and
TB programmes in Zimbabwe; and to understand and characterize
adverse drug reactions (ADR’s) or individual case safety reports
(ICSRs) due to ARV and anti-TB medicines.
Protecting Your Right to Quality Medicines and Medical Devices
TSR of anti-TBs and ARVs- Pilot PhaseResults:
Age range was 0.9-76 years (median = 38 years)
In 83% of the reports, one ADR was reported per patient
In 11% of the reports, two ADRs were reported per patient
In 6% of the reports, three ADRs were reported per patient
Protecting Your Right to Quality Medicines and Medical Devices
TSR of anti-TBs and ARVs- Pilot PhaseResults: The majority of ADR’s reported were mainly cutaneous in nature
Cutaneous (44%)
CNS (27%)
metabolic in nature (11%)
Protecting Your Right to Quality Medicines and Medical Devices
TSR of anti-TBs and ARVs- Pilot PhaseResults: Efavirenz vs Nevirapinelower odds of cutaneous reactions compared to those on Nevirapine containing regimens (OR=0.07, p-value<0.0005)
higher odds of CNS type of reactions compared to those on NVP (OR=6.0; p-value<0.0005).
gastrointestinal reactions which were more frequent in those on Efavirenz containing regimens (OR=3.3, p-value=0.03).
Protecting Your Right to Quality Medicines and Medical Devices
TSR of anti-TBs and ARVs- Pilot PhaseConclusion:
Pharmacovigilance activities need to be strengthened and included as part of clinical care especially for patient on ART and anti-TB treatment including essential medicines.
Protecting Your Right to Quality Medicines and Medical Devices
TSR of anti-TBs and ARVs- Pilot PhaseConclusion:The TSR pilot phase demonstrated significant increase in ADR reporting and considered relatively a feasible cost effective method hence TSR was scaled up to the main phase program.
Protecting Your Right to Quality Medicines and Medical Devices
TSR of anti-TBs and ARVs- Pilot PhaseConclusion:
Further in depth analysis of ICSRs of medicines reported such as tenofovir in combination with other anti-retrovirals is required.
Protecting Your Right to Quality Medicines and Medical Devices
Resources
• Drug Information Bulletin (MCAZ website)• ADR reporting form (MCAZ website, email, request for hard copies)• Product defect reporting form(MCAZ website, email, request for hard
copies)• TSR protocol
Protecting Your Right to Quality Medicines and Medical Devices